TAF6L Antibody

What is TAF6L and what is its function in cellular processes?

TAF6L (TAF6-like RNA polymerase II p300/CBP-associated factor-associated factor 65 kDa subunit 6L), also known as PAF65A, is a 622 amino acid nuclear protein that functions as part of the PCAF (p300/CBP-associated factor) histone acetylase complex. It plays a critical role in coordinating the activities required for RNA polymerase II-mediated transcription, which involves more than 70 polypeptides. TAF6L is a component of transcription factor IID (TFIID), which binds to core promoters to position the polymerase properly, serves as a scaffold for assembly of the transcription complex, and acts as a channel for regulatory signals . Recent research has identified TAF6L as a novel epigenetic regulator that maintains self-renewal of embryonic stem cells by regulating the expression of pluripotency genes .

What is the molecular structure and localization of TAF6L?

TAF6L is a nuclear protein with a calculated molecular weight of approximately 67-68 kDa, although it is typically observed at around 70 kDa in Western blot analyses. This discrepancy between calculated and observed molecular weight may be due to post-translational modifications . TAF6L has been shown to interact with other transcriptional regulators, including TAF9 and the transcription initiation protein SPT3 homolog . As a component of the PCAF histone acetylase complex, TAF6L is primarily localized in the nucleus, consistent with its role in transcriptional regulation .

What are the recommended experimental applications for TAF6L antibodies?

TAF6L antibodies have been validated for several experimental applications including Western Blotting (WB), Immunoprecipitation (IP), and Immunohistochemistry (IHC). For Western blotting, dilutions typically range from 1:500 to 1:6000, while immunoprecipitation applications generally require dilutions between 1:50 and 1:200. For immunohistochemistry, researchers should use dilutions ranging from 1:250 to 1:1000 . It's important to note that optimal antibody dilutions may be sample-dependent, and titration is recommended for each experimental system to achieve optimal results .

How should TAF6L antibodies be stored and handled to maintain reactivity?

TAF6L antibodies should be stored at -20°C, where they typically remain stable for up to 12 months. It's crucial to avoid repeated freeze-thaw cycles as these can compromise antibody integrity and performance. Many commercial TAF6L antibodies are supplied in a phosphate-buffered solution (pH 7.4) containing stabilizers and 50% glycerol . When shipping is necessary, antibodies should be transported on ice packs, and upon receipt, they should be immediately stored at the recommended temperature .

How can TAF6L antibodies be utilized to investigate pluripotency networks in embryonic stem cells?

TAF6L plays a crucial role in maintaining the self-renewal capability of embryonic stem cells by regulating pluripotency gene expression. Research has shown that knockout of TAF6L results in significant reduction of embryonic stem cell-specific genes, including Oct4/Pou5f1, Nanog, Esrrb, Tbx3, Zfp42, and Klf4, as well as c-Myc . Researchers can utilize TAF6L antibodies in chromatin immunoprecipitation (ChIP) assays to identify genomic binding sites of TAF6L in pluripotent cells. Combined with RNA-sequencing data from TAF6L knockout models, this approach can elucidate the direct transcriptional targets of TAF6L and its contribution to pluripotency networks. Additionally, co-immunoprecipitation experiments using TAF6L antibodies can reveal protein interaction partners that may be critical for maintaining the pluripotent state .

What methodological approaches can be used to study TAF6L's role in histone acetylation complexes?

As a component of the PCAF histone acetylase complex, TAF6L is involved in epigenetic regulation through histone modification. To investigate this function, researchers can employ several advanced methodological approaches. ChIP-seq experiments using TAF6L antibodies can map genome-wide binding patterns in relation to histone acetylation marks. Sequential ChIP (re-ChIP) can be used to determine co-occupancy of TAF6L with other components of the PCAF complex at specific genomic loci. Additionally, researchers can perform in vitro histone acetyltransferase (HAT) assays with immunoprecipitated TAF6L-containing complexes to assess their enzymatic activity. Mass spectrometry analysis following TAF6L immunoprecipitation can identify post-translational modifications on TAF6L itself that might regulate its function within the PCAF complex .

What controls should be included when using TAF6L antibodies in Western blotting experiments?

When designing Western blotting experiments with TAF6L antibodies, several controls are essential to ensure result validity. Positive controls should include lysates from cell lines known to express TAF6L, such as LNCaP, HeLa, HEK-293, Jurkat, K-562, HSC-T6, or NIH/3T3 cells . For negative controls, researchers should consider using lysates from TAF6L knockout cell lines, when available, or lysates treated with TAF6L-specific siRNA to validate antibody specificity. Additionally, peptide competition assays, where the antibody is pre-incubated with the immunizing peptide before the experiment, can confirm binding specificity. It's also crucial to verify that the observed band is at the expected molecular weight (~68-70 kDa) . For quantitative comparisons, normalization to appropriate loading controls (housekeeping proteins) is necessary, and researchers should validate that the signal falls within the linear range of detection.

How should researchers design experiments to investigate TAF6L's function in transcriptional regulation?

To comprehensively investigate TAF6L's role in transcriptional regulation, a multi-faceted experimental approach is recommended. Begin with gene expression analysis using RNA-seq or qRT-PCR to compare transcriptome profiles between wild-type and TAF6L-depleted cells. This should be complemented with ChIP-seq to identify direct TAF6L binding sites across the genome . For mechanistic insights, researchers should perform reporter gene assays using promoters of TAF6L target genes in wild-type and TAF6L-knockout backgrounds. To understand the functional consequences of TAF6L depletion, cellular phenotype assays should be conducted, such as proliferation assays, cell cycle analysis, or differentiation assays in stem cell contexts . For rescue experiments, researchers should express exogenous TAF6L in knockout cells to confirm that observed phenotypes are directly attributable to TAF6L loss. When interpreting results, it's important to consider potential compensatory mechanisms by related factors, such as TAF5L, which shares functional overlap with TAF6L in maintaining stem cell self-renewal .

How can researchers address inconsistent TAF6L antibody staining in immunohistochemistry?

Inconsistent staining in immunohistochemistry using TAF6L antibodies can result from several factors. First, optimize antigen retrieval methods—for TAF6L antibodies, TE buffer at pH 9.0 is often recommended, although citrate buffer at pH 6.0 may be used as an alternative . Verify the antibody dilution; for IHC applications, dilutions typically range from 1:250 to 1:1000, but optimal concentration should be determined experimentally for each tissue type . Consider fixation variables, as overfixation can mask epitopes while underfixation may compromise tissue morphology. Blocking protocols should also be optimized to reduce background staining. For tissues with potentially low TAF6L expression, consider signal amplification methods. If inconsistencies persist, validate antibody specificity using positive control tissues (such as human breast cancer tissue, which has been verified for TAF6L antibody reactivity) and negative controls (such as IgG isotype controls or tissues from TAF6L knockout models). Finally, consider batch-to-batch variability of antibodies and standardize protocols across experiments.

How should researchers interpret discrepancies between calculated and observed molecular weights of TAF6L in Western blots?

The calculated molecular weight of TAF6L is approximately 67-68 kDa, but it is frequently observed at around 70 kDa in Western blot analyses . This discrepancy is a common phenomenon in protein detection and can be attributed to several factors. Post-translational modifications, such as phosphorylation, glycosylation, or ubiquitination, can significantly alter the mobility of proteins during gel electrophoresis. TAF6L may undergo such modifications as part of its regulatory mechanism within the PCAF complex. Additionally, the highly charged nature of transcription factors can affect their migration patterns in SDS-PAGE. Researchers should verify that the observed band represents TAF6L through additional validation techniques, such as immunoprecipitation followed by mass spectrometry, or by knockdown/knockout experiments to confirm band disappearance. When multiple bands are observed, researchers should consider the possibility of isoforms, degradation products, or differentially modified forms of TAF6L. Western blotting under different conditions (reducing vs. non-reducing, different gel percentages) may provide additional insights into the nature of the observed bands .

How can TAF6L antibodies be used to investigate the transition from pluripotency to differentiation?

TAF6L has been identified as a regulator of embryonic stem cell self-renewal, with its expression levels significantly decreasing upon differentiation . Researchers investigating pluripotency transitions can utilize TAF6L antibodies in time-course experiments to monitor TAF6L protein levels during differentiation protocols. ChIP-seq experiments at different time points of differentiation can reveal dynamic changes in TAF6L genomic binding, potentially identifying enhancers and promoters that are differentially regulated during this transition. Co-immunoprecipitation studies using TAF6L antibodies can identify changing protein interaction networks as cells exit pluripotency. Notably, research has shown that TAF6L knockout embryonic stem cells exhibit biased differentiation toward the trophoectoderm lineage, suggesting a role for TAF6L in lineage specification . Researchers can use immunofluorescence with TAF6L antibodies to examine subcellular localization changes during differentiation, potentially revealing regulatory mechanisms. When interpreting results, it's important to consider that TAF6L functions in concert with other factors like TAF5L, and their combined deletion may reveal more pronounced phenotypes than individual knockouts .

What methodological considerations are important when using TAF6L antibodies to study somatic cell reprogramming?

Somatic cell reprogramming studies involving TAF6L require careful methodological planning. Research has demonstrated that targeting TAF6L via sgRNAs in reprogrammable mouse embryonic fibroblasts affected the generation of stable transgene-independent induced pluripotent stem cells (iPSCs) . When designing reprogramming experiments, researchers should consider using doxycycline-inducible systems with appropriate reporters (such as Oct4-GFP) to track reprogramming efficiency. For TAF6L knockdown studies, timing is critical—TAF6L appears to be particularly important for acquiring transgene independence rather than initial reprogramming steps . Researchers should verify TAF6L knockout/knockdown efficiency through both genomic (e.g., amplicon sequencing) and protein-level analyses using TAF6L antibodies. Flow cytometry using pluripotency markers (e.g., OCT4, EPCAM) at defined time points can quantitatively assess reprogramming progression. When analyzing results, researchers should distinguish between effects on reprogramming initiation versus stabilization of the pluripotent state. Additionally, rescue experiments with exogenous TAF6L expression can confirm that observed phenotypes are directly attributable to TAF6L function .

How can researchers verify the specificity of TAF6L antibodies across different experimental systems?

Verifying TAF6L antibody specificity is crucial for experimental reliability. Researchers should implement a multi-faceted validation approach beginning with Western blot analysis in known TAF6L-expressing cell lines (such as LNCaP, HeLa, HEK-293, Jurkat, K-562, HSC-T6, or NIH/3T3 cells) . Confirmation should include TAF6L-depleted systems using siRNA knockdown, CRISPR knockout, or shRNA approaches to demonstrate disappearance or significant reduction of the target band. Peptide competition assays, where the antibody is pre-incubated with the immunizing peptide, can confirm binding specificity. For immunoprecipitation experiments, mass spectrometry analysis of immunoprecipitated proteins can verify that TAF6L is indeed being captured. When using the antibody in new cell types or tissues, researchers should first validate TAF6L expression at the mRNA level using qRT-PCR or RNA-seq data. Cross-reactivity testing with related proteins, particularly other TAF family members, is advisable. Researchers should also confirm antibody performance across species if working with non-human models, as reactivity has been reported for human, mouse, and rat samples .

What bioinformatic approaches can complement TAF6L antibody-based chromatin studies?

Bioinformatic analyses can substantially enhance the interpretation of TAF6L chromatin studies. After ChIP-seq experiments using TAF6L antibodies, researchers should perform peak calling to identify TAF6L binding sites, followed by motif enrichment analysis to identify DNA sequences preferentially bound by TAF6L-containing complexes. Integration with gene expression data from TAF6L-depleted cells can identify direct transcriptional targets. Comparison of TAF6L binding sites with known histone modification datasets (particularly acetylation marks associated with the PCAF complex) can reveal the relationship between TAF6L binding and local chromatin state. Pathway enrichment analysis of TAF6L-bound genes can identify biological processes under TAF6L regulation. Co-occupancy analysis with other transcription factors and chromatin regulators can place TAF6L within broader regulatory networks. In pluripotency studies, researchers should analyze the overlap between TAF6L binding sites and known binding sites of core pluripotency factors (OCT4, SOX2, NANOG) . When analyzing TAF6L binding in different cellular contexts, comparative analyses can identify cell type-specific versus shared binding sites, providing insights into context-dependent functions of TAF6L.